STING1 and neoplasm: Numerous studies have shown that STING agonists exhibit potent anti‐tumor activity, opening the way for developing STING‐based cancer immunotherapy.[59] However, although the STING agonists can activate the STING pathway to trigger an anti‐tumor immune response in cancer treatment, it still has some shortcomings, such as off‐target effects and toxicity.[60] Therefore, the use of synthetic biology technology to engineer bacteria to produce and release STING agonists after colonization on tumor sites has become a preferred solution.